The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
Sep. 07, 2017
Applicant:
Pliant Therapeutics, Inc., Redwood City, CA (US);
Inventors:
Lan Jiang, Foster City, CA (US);
David John Morgans, Jr., Los Altos, CA (US);
Gustave Bergnes, Pacifica, CA (US);
Chun Chen, Albany, CA (US);
Hui Li, Santa Clara, CA (US);
Patrick Andre, Short Hills, NJ (US);
Randall L. Halcomb, Foster City, CA (US);
Jacob Cha, Burlingame, CA (US);
Timothy Hom, Sunnyvale, CA (US);
Assignee:
Pliant Therapeutics, Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 213/74 (2006.01); C07D 233/70 (2006.01); C07D 233/88 (2006.01); C07D 241/06 (2006.01); C07D 241/08 (2006.01); C07D 263/28 (2006.01); C07D 265/08 (2006.01); C07D 277/18 (2006.01); C07D 279/06 (2006.01); A61P 9/00 (2006.01); A61P 17/00 (2006.01); A61P 13/12 (2006.01); A61P 1/00 (2006.01); A61P 11/00 (2006.01); A61P 1/16 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61P 1/00 (2018.01); A61P 1/16 (2018.01); A61P 9/00 (2018.01); A61P 11/00 (2018.01); A61P 13/12 (2018.01); A61P 17/00 (2018.01); C07D 213/74 (2013.01); C07D 233/70 (2013.01); C07D 233/88 (2013.01); C07D 241/06 (2013.01); C07D 241/08 (2013.01); C07D 263/28 (2013.01); C07D 265/08 (2013.01); C07D 277/18 (2013.01); C07D 279/06 (2013.01);
Abstract
The invention relates to compounds of formula (I): or a salt thereof, wherein R, A, L, and Rand n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.